Aggrastat Injection, Solution
NDC 25208-002
Product Information
Aggrastat (tirofiban) is a NDA-approved product labeled by Medicure International Inc. This medication is typically used as a decreased platelet aggregation [pe]. It is supplied as a injection, solution for intravenous administration. This product entry covers the primary NDC 25208-002 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 25208-002?
What are the uses of this product?
What are Active Ingredients of this product?
- TIROFIBAN HYDROCHLORIDE 5 mg/100mL - Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TIROFIBAN HYDROCHLORIDE (UNII: 6H925F8O5J)
- TIROFIBAN (UNII: GGX234SI5H) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)
- TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1737466 - tirofiban 5 MG in 100 ML Injection
- RxCUI: 1737466 - 100 ML tirofiban 0.05 MG/ML Injection
- RxCUI: 1737466 - tirofiban (as hydrochloride) 5 MG per 100 ML Injection
- RxCUI: 1737466 - tirofiban 50 MCG per 1 ML Injection
- RxCUI: 1737468 - AGGRASTAT 5 MG in 100 ML Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.